Achieving Commercial Success through the Implementation
of Amorphous Techniques
Amorphous pharmaceutical materials are now being
recognised as an attractive alternative route for solid state development,
partly due to the increasing proportion of insoluble drug molecules in
development.
Owing to the lack of an ordered crystal lattice,
amorphous forms require minimal energy and therefore offer enhanced solubility,
dissolution rate, and bioavailability - properties which are all integral to
the effectiveness and success of future medicines.
Currently, several amorphous drugs have made it to
market, but in many cases stabilising amorphous systems while maintaining these
physico-chemical advantages still remains a major challenge in the
pharmaceutical arena.
For that reason, Amorphous Pharmaceutical Materials 2010
will explore the results and knowledge acquired over the years on perfecting
the art of amorphous formation and stabilisation. This will thus ensure
consistency of amorphous drugs from the laboratory to manufacture, with the
ultimate aim of realising the commercial potential of amorphous forms in
pharmaceutical drugs.
The Expert Speaker Panel includes:
- Dr Marcus Brewster, Distinguished Research Fellow and
Head of ChemPharm Research, Johnson & Johnson Pharmaceutical Research and Development
- Dr Brian Padden, Section Manager, Abbott Laboratories
- Dr Conrad Winters, Senior Director Pharmaceutics, Xenon
Pharmaceuticals
- Dr Zeren Wang, Director Pharmaceutics, Boehringher
Ingelheim
- Dr Anne Kavanagh, Crystallisation Scientist, AstraZeneca
- Mr Andrew Theophilus MRSC, Team Leader, Physical
Properties and Analytical Sciences, GlaxoSmithKline
- Dr Brian Luisi, Research Scientist, Vertex
Pharmaceuticals
- Dr Marco Gil, R & D Particle Design Senior
Engineer, Hovione
Event only price: 1899 EUR
Register by 18th June and receive up to €500 off!
T: +44(0)20 7368 9300
Language:
English
Call for paper:
Deadline for submission is 27 September 2010
Organization:
Pharma IQ (a division of IQPC)
Contact person:
Pharma IQ Team
Email:
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Conferences 